Royalty Pharma is followed by the analysts listed above as of February 2023. Royalty Pharma believes the list to be complete, but can provide no assurances. The list above may change as firms initiate or discontinue coverage. Please note that any statements, opinions, estimates or forecasts regarding Royalty Pharma’s performance made by these analysts are theirs alone and do not represent statements, opinions, forecasts or predictions of Royalty Pharma or its management. Royalty Pharma does not by its reference above or distribution imply its endorsement of, adoption or concurrence with such information, conclusions or recommendations. Moreover, Royalty Pharma does not and will not distribute copies of analysts’ reports to investors or other persons.